





# Identification of drugs subtype-selective for $\alpha_{2A}$ -, $\alpha_{2B}$ -, and $\alpha_{2C}$ -adrenoceptors in the pig cerebellum and kidney cortex

Anna Wikberg-Matsson a, Jarl E.S. Wikberg b, Staffan Uhlén b,\*

<sup>a</sup> Department of Ophtalmology, Academic Hospital, Uppsala, Sweden
<sup>b</sup> Department of Pharmaceutical Biosciences, Division of Pharmacology, Uppsala University, Uppsala, Sweden

Received 27 February 1995; revised 8 June 1995; accepted 9 June 1995

#### **Abstract**

The radioligands [ $^3$ H]MK912 and [ $^3$ H]RX821002 were used to label  $\alpha_{2A}$ -,  $\alpha_{2B}$ -, and  $\alpha_{2C}$ -adrenoceptors of the pig cerebellum and kidney cortex. By inclusion of the  $\alpha_{2A}$ -adrenoceptor-selective drug, BRL44408, and using a 'multi-curve' experimental design all the three porcine  $\alpha_2$ -adrenoceptor subtypes could be characterized pharmacologically. The data indicate that the pig  $\alpha_2$ -adrenoceptor subtypes are pharmacologically more related to human  $\alpha_2$ -adrenoceptor subtypes than to the rodent  $\alpha_2$ -adrenoceptors. We suggest a set of drugs that are useful for the delineation of the pig  $\alpha_2$ -adrenoceptor subtypes.

Keywords:  $\alpha_2$ -Adrenoceptor subtype; [3H]MK912; [3H]RX821002; (Pig)

### 1. Introduction

Based on structural and pharmacological evidence, the  $\alpha_2$ -adrenoceptors are currently subclassified into at least three subtypes: the  $\alpha_{2A}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptor subtypes (see Bylund et al., 1994). Although additional subtypes have been proposed, only three distinct  $\alpha_2$ -adrenoceptors have unequivocally been shown to coexist within one species. Each of the species homologues of the  $\alpha_{2A}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptors have been cloned from humans, rats and mice (see Bylund et al., 1994, for references), as well as from guinea pigs (Dr. J.W. Regan, personal communication). In addition, the porcine  $\alpha_{2A}$ -adrenoceptor subtype (Guyer et al., 1990) and the opossum  $\alpha_{2C}$ -subtype have been cloned (Blaxall et al., 1994). Using radioligand binding techniques three native  $\alpha_2$ -adrenoceptor subtypes have been detected in the rat (Uhlén et al., 1992) and guinea pig (Uhlén et al., 1995). The pharmacological correlations between the cloned receptors expressed in cell lines with the corresponding native  $\alpha_2$ -adrenoceptors in the rat tissues were shown to be In the present study we have extended to the pig our previous investigations of native  $\alpha_2$ -adrenoceptors, the aim being to identify useful ligands for labelling and identifying the  $\alpha_{2A}$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$  subtypes in this species. The pig cerebellum and kidney cortex proved to be useful sources for the porcine  $\alpha_2$ -adrenoceptor subtypes. The methods developed may also prove useful for detecting small populations of  $\alpha_2$ -adrenoceptor subtypes in other tissues of the pig. Since large quantities of pig tissues can be obtained from local slaughterhouses, pig tissues can be used to identify scarce populations of  $\alpha_2$ -adrenoceptors, e.g. in different parts of the eye, blood vessels, synaptosomes etc.

### 2. Materials and methods

### 2.1. Membrane preparations

Pig cerebellums and kidneys were obtained from the local slaughterhouse. The excised tissues were immediately placed on ice, and then cut into smaller pieces and frozen at  $-80^{\circ}$ C within 1 h. Membranes were prepared from thawed samples essentially as described previously (Uhlén and Wikberg, 1991a). The final pel-

excellent (Harrison et al., 1991; Uhlén et al., 1992, 1993; Xia et al., 1993).

<sup>\*</sup> Corresponding author. Department of Pharmaceutical Biosciences, Division of Pharmacology, Box 591, Uppsala University, S-751 24 Uppsala, Sweden. Tel. + 46-18-17 41 08, fax + 46-18-55 97 18.

lets were resuspended at concentrations  $\sim 1.4$  mg protein/ml for cerebellum and  $\sim 2.8$  mg protein/ml for kidney cortex using 1.5 mM EDTA, 50 mM Tris-HCl, pH 7.5, and the suspensions were frozen and stored at  $-80^{\circ}$ C until used for radioligand binding. Protein was measured according to Lowry et al. (1951).

### 2.2. Binding studies

Radioligand binding was performed essentially as described by Uhlén and Wikberg (1991a) by, unless otherwise stated, incubating 140-280 µg of the membranes in 150  $\mu$ l of 1 mM EDTA, 100  $\mu$ M Gpp(NH)p (guanyl-5'-yl-imido-diphosphate), 140 mM NaCl, 33 mM Tris-Cl, pH 7.5 with  $[^{3}H]MK912$  or  $|^{3}H]RX821002$  and drugs for 1 h at 25°C and then filtering and washing on Whatman GF/C filters. All assays were performed in duplicate. Non-specific binding was determined in the presence of 2  $\mu$ M RX821002 when [<sup>3</sup>H]MK912 was used, and with 2  $\mu$ M MK912 when  $[^3H]RX821002$  was used. Computer modelling of the data, using the 'multi-curve' approach, was performed essentially as described by Uhlén and Wikberg (1991b) using the BindAid radioligand binding analysis package (Wan System, Umeå, Sweden) on a MacIntosh computer.

### 2.3. Isotopes, drugs and chemicals

[<sup>3</sup>H]MK912 ((2*S*,12*bS*)1',3'-dimethylspiro (1,3,4,5', 6,6',7,12*b*-octahydro-2*H*-benzo[*b*]furo[2,3-*a*]quinazoline)-2,4'-pyrimidin-2'-one; 81 Ci/mmol) was a kind gift from NEN-DuPont; [<sup>3</sup>H]RX821002 ((1,4-benzodioxan-2-methoxy-2-yl)-2-imidazoline; 51 Ci/mmol) was from Amersham; ARC239 (2-(2,4-(*O*-methoxyphenyl)-piperazin-1-yl)-ethyl-4,4-dimethyl-1,3(2*H*,4*H*)-isoquinolindione) from Thomae, Biberach, Germany; BRL44408 (2-(2*H*-(1-methyl-1,3-dihydroisoindole) methyl)-4,5-dihydroimidazole) and BRL41992 (1,2-dimethyl-2,3,9,13*b*-tetrahydro-1*H*-dibenzo[*c*, *f*]imidazo-[1,5-*a*]azepine) from Beecham, Essex, UK; MK912 from Merck; oxymetazoline from Draco, Lund, Sweden; rau-

wolscine from Carl Roth, Karlsruhe, Germany; RX821002 from Reckitt and Coleman, Kingston upon Hull, UK; spiroxatrine and WB4101 (2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane) from RBI, Natick, MA, USA.

#### 3. Results

3.1. Determination of the  $K_d$  values of [ ${}^3H$ ]MK912 for  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors in the pig cerebellum


In our previous studies we showed that [3H]MK912 labelled both  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors in the rat spinal cord, cerebral cortex and cerebellum (Uhlén et al., 1992; Uhlén and Wikberg, 1992). Among these tissues the proportion of  $\alpha_{2C}$ -adrenoceptors was highest in the cerebellum, where they amounted to 15% of the total number of  $\alpha_2$ -adrenoceptors. In order to probe  $\alpha_2$ -adrenoceptor subtypes in the pig cerebellum we first evaluated BRL44408 because this compound had been shown in other species to be  $\alpha_{2A}$ - versus  $\alpha_{2C}$ -adrenoceptor selective. The labelled ligand used was [3H]MK912. This experiment revealed a clearly biphasic competition curve for BRL44408, implicating that the pig cerebellum also contains both  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors. In order to determine the  $K_d$  values of [3H]MK912 for the two  $\alpha_2$ -adrenoceptors we performed combined saturation and competition experiments. In these tests five different binding curves were obtained on the same occasion: one plain saturation curve for [3H]MK912, another saturation curve of [3H]MK912 in the presence of a mask of 167 nM BRL44408, a third saturation curve in the presence of 2 µM RX821002, a fourth and fifth curve representing competition of BRL44408 using two different fixed concentrations of [3H]MK912 (about 0.4 nM and 1.7 nM, respectively). All the curves were subjected to simultaneous calculation in the computer. [In these tests the two competition curves help to define the proportion of  $\alpha_{2A}/\alpha_{2C}$ -adrenoceptors, thus increasing


Table 1  $K_{\rm d}$  values of [<sup>3</sup>H]MK912 and [<sup>3</sup>H]RX821002 at porcine  $\alpha_{\rm 2A}$ -,  $\alpha_{\rm 2B}$ - and  $\alpha_{\rm 2C}$ -adrenoceptors


Drug	Cerebellum					
	(n)	$K_{\rm d} \alpha_{\rm 2A} (\rm nM)$	$K_{\rm d} \alpha_{\rm 2C}$ (nM)	$\alpha_{2A}$ sites (%)		
[ <sup>3</sup> H]MK912	6	$1.39 \pm 0.35$	$0.12 \pm 0.02$	$90.6 \pm 1.1$		
	Kidney cort	ex				
	(n)	$K_{\rm d} \alpha_{\rm 2A} (\rm nM)$	$K_{\rm d} \alpha_{\rm 2B} (\rm nM)$	$\alpha_{2A}$ sites (%)		
[ <sup>3</sup> H]RX821002	3	$0.86 \pm 0.12$	$4.52 \pm 0.83$	$48.3 \pm 6.4$		

 $K_d$  values of [3H]MK912 for  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors determined in pig cerebellar membranes, and  $K_d$  values of [3H]RX821002 for  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptors determined in pig kidney cortex membranes. The data are based on the combined saturation and competition experiments shown in Figs. 1 and 2. Also shown in the table are the proportions of the  $\alpha_2$ -adrenoceptors of the  $\alpha_{2A}$  subtype in each tissue. Numbers are given as means  $\pm$  S.E.M. of six and three experiments, respectively, each performed with duplicate determinations. n = number of experiments.

the accuracy of the determination of the  $K_{\rm d}$  values for [ $^3$ H]MK912. In the saturation tests BRL44408 blocks the majority of the  $\alpha_{\rm 2A}$ -adrenoceptors, while leaving most of the  $\alpha_{\rm 2C}$ -adrenoceptor sites untouched. RX821002 was included to help define the non-specific binding. (See Uhlén and Wikberg, 1991b, for a further discussion on this topic).] The results are shown in Fig. 1A–C and in Table 1. As can be seen from Table 1 the









 $K_{\rm d}$  value of [<sup>3</sup>H]MK912 was 1.39 nM and 0.116 nM for the  $\alpha_{\rm 2A}$ - and  $\alpha_{\rm 2C}$ -adrenoceptor, respectively (a 12-fold difference in affinity; n = 6). The number of sites was  $119 \pm 20$  fmol/mg protein (91%), and  $11.4 \pm 1.0$ fmol/mg protein (9%) of  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors, respectively. Fig. 1A shows Rosenthal plots of the plain and BRL44408-masked [3H]MK912 saturation curves. As can be seen, the non-masked [3H]MK912 curve is clearly non-linear, indicating the presence of high- and low-affinity binding sites. For the BRL44408-masked curve practically all low-affinity sites are blocked, while most high-affinity sites remain untouched, indicating that [3H]MK912 has the higher affinity for the low-affinity BRL44408 site (i.e. the  $\alpha_{2C}$ -adrenoceptor). Fig. 1B shows the non-transformed data of Fig. 1A. In accordance with the results of Fig. 1A most of the specific sites become saturated by [3H]MK912 as soon as at a concentration of about 0.2 nM of [3H]MK912, when the BRL44408 mask is present. These results reflects the high affinity of [3H]MK912 for the remaining  $\alpha_{2C}$ -adrenoceptors. In the non-masked curve many additional sites become progressively labelled in the concentration range of about 0.2-2 nM of [<sup>3</sup>H]MK912. This reflects the presence of a large population of  $\alpha_{2A}$ -adrenoceptors for which [3H]MK912 has lower affinity. Fig. 1C shows the two competition curves of BRL44408 which were obtained on the same occasion as the saturation curves with two different fixed concentrations of [3H]MK912. It may be seen in Fig. 1C that increasing [3H]MK912 from 0.41 nM to 1.74 nM gives an increase in the displaceable component for which BRL44408 has high affinity (i.e. the labelled  $\alpha_{2A}$ -adrenoceptors) while the low-affinity component (i.e. the labelled  $\alpha_{2C}$ -adrenoceptors) remains of the same size. These data again support the conclusion that [ ${}^{3}$ H]MK912 shows the higher affinity for the  $\alpha_{2C}$ adrenoceptors. It may be noted that the solid lines in Fig. 1 represent the simultaneous fit of all the data to a two-site model. As can be seen in Fig. 1, the computer drawn curves fit the data well, indicating the validity of the model.


Fig. 1. Saturation and competition experiments performed on pig cerebellar membranes using [3H]MK912 as labelled ligand. Shown in B are saturation curves for total [3H]MK912 binding (1), binding of [3H]MK912 in the presence of 167 nM BRL44408 (•), and binding in the presence of 2  $\mu$ M RX821002 ( $\blacktriangle$ ). Shown in C are competition curves of BRL44408 obtained in the presence of 1.74 nM ( ) and 0.41 nM (•) of [3H]MK912, using the same batch of cerebellar membranes and performed on the same occasion as the experiment shown in panel B. The lines represent the computer drawn fits from the simultaneous fitting of the data in B and C, assuming that ligands bound reversibly to two independent sites according to the law of mass action. In A is shown the Rosenthal transform of the data shown in B; ■ represents the total specific binding, and • the specific binding obtained in the presence of 167 nM BRL44408. Panels A-C show one representative experiment out of six showing essentially the same results.

# 3.2. Determination of the $K_d$ values of [ ${}^3H$ ]RX821002 for $\alpha_{2A}$ - and $\alpha_{2B}$ -adrenoceptors in the pig kidney cortex

In a previous study we have shown that the rat kidney contains both  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptors (Uhlén and Wikberg, 1991b). In the present study we evaluated the presence of  $\alpha_2$ -adrenoceptor subtypes in







the pig kidney cortex. Pilot experiments showed that the non-specific binding of  $\sim 1.2$  nM [<sup>3</sup>H]MK-912 amounted to almost 50% of the total binding in this tissue. This high non-specific binding made [3H]MK-912 unsuitable for our studies. We therefore evaluated an alternative radioligand, [3H]RX-821002 (Langin et al., 1989), which we found to label the kidney  $\alpha_2$ adrenoceptors without the non-specific binding being disturbingly high. Competition studies using the  $\alpha_{2A}$ selective drug, BRL44408, revealed that [3H]RX821002 labelled two sites in the pig kidney cortex, the sites presumably representing  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptors. In order to determine the  $K_{\rm d}$  values of [³H]RX821002 for these sites we made combined saturation and competition curves according to a design similar to that described above for the cerebellum. Thus, five curves were obtained in the same experiment: one plain saturation curve of [3H]RX821002, another saturation curve in the presence of BRL44408 (316 nM), a third saturation curve in the presence of 2  $\mu$ M MK912 to define the non-specific binding, a fourth and a fifth curves being competition curves of BRL44408 using two different fixed concentrations of [3H]RX821002 (about 0.9 nM and 4 nM, respectively). The results of these experiments are shown in Table 1 and in Fig. 2. As is shown in Table 1, the  $K_d$  value of [ $^3$ H]RX821002 was found to be 0.85 and 4.5 nM for the  $\alpha_{\rm 2A}\text{-}$  and  $\alpha_{\rm 2B}\text{-}$ adrenoceptor, respectively (a 5-fold difference; n = 3). The number of sites was  $8.5 \pm 11$  (48%) and  $9.2 \pm 1.4$ (52%) fmol/mg protein of  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptors, respectively. The Rosenthal plot of the plain saturation curve is slightly curved indicating the presence of two binding sites (Fig. 2A). It may also be noticed that the Rosenthal plot of the BRL44408masked saturation curves (the lower curve in Fig. 2A) is a straight line with a very shallow slope. This is because most of the  $\alpha_{2A}$ -adrenoceptors are blocked by 316 nM of BRL44408, while some low-affinity  $\alpha_{2B}$ adrenoceptors remain for [3H]RX821002 to bind to.

Fig. 2. Saturation and competition experiments performed on pig kidney cortex membranes using [3H]RX821002 as labelled ligand. Shown in B are saturation curves for the total [3H]RX821002 binding (■), the binding in the presence of 316 nM BRL44408 (•), as well as in the presence of 2  $\mu$ M MK912 ( $\blacktriangle$ ). Shown in C are competition curves of BRL44408 obtained using 4.07 nM (■) and 0.93 nM (●) of [3H]RX821002, and using the same batch of kidney cortex membranes and assayed on the same occasion as the experiment shown in panel B. The lines represent the computer drawn fits from the simultaneous fitting of the data in B and C assuming that ligands bound reversibly to two independent sites according to the law of mass action. In A is shown the Rosenthal transform of the data shown in B; ■ represents the total specific binding, and • the specific binding obtained in the presence of 316 nM BRL44408. Panels A-C represents one experiment out of three showing essentially the same results.

Table 2 Drug  $K_d$  values at porcine  $\alpha_{2A}$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$ -adrenoceptors

Drug	Cerebellum			Kidney cortex		
	$\overline{(n)}$	$K_{\rm d} \alpha_{\rm 2A} ({\rm nM})$	$K_{\rm d} \alpha_{\rm 2C} (\rm nM)$	$\overline{(n)}$	$K_{\rm d} \alpha_{\rm 2A} ({\rm nM})$	$K_{\rm d} \alpha_{\rm 2B} (\rm nM)$
RX821002	3	$1.22 \pm 0.69$	$1.90 \pm 0.52$	3	1.36 ± 0.64	$3.50 \pm 0.42$
MK912	3	$1.35 \pm 0.64$	$0.16 \pm 0.09$	4	$1.16 \pm 0.37$	$1.28 \pm 0.18$
Rauwolscine	3	$1.63 \pm 0.15$	$0.41 \pm 0.11$	3	$2.92 \pm 0.39$	$3.54 \pm 0.96$
WB4101	4	$4.90 \pm 0.67$	$2.04 \pm 0.54$	5	$12.3 \pm 2.0$	$52.7 \pm 15.2$
BRL44408	8	$8.07 \pm 2.29$	181 $\pm$ 34	10	$7.41 \pm 0.90$	$481 \pm 85$
Oxymetazoline	3	$13.7 \pm 9.0$	$172 \pm 60$	5	$26.7 \pm 7.9$	$2150 \pm 660$
Spiroxatrine	3	$28.1 \pm 2.4$	$1.26 \pm 0.17$	3	$57.1 \pm 4.3$	$2.10 \pm 0.27$
BRL41992	4	$188 \pm 49$	$230 \pm 45$	7	$300 \pm 42$	$20.1 \pm 5.9$
ARC239	3	961 $\pm$ 85	$27.7 \pm 1.0$	6	$1310 \pm 210$	$38.7 \pm 6.1$

Drug  $K_d$  values determined from competition experiments at  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors labelled by  $\sim 0.35$  nM of [ $^3$ H]MK912 in pig cerebellar membranes, or  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptors labelled by  $\sim 3.5$  nM of [ $^3$ H]RX821002 in pig kidney cortex membranes. For each experiment three competition curves were obtained as described in the legend to Fig. 3 and 4, and the data were simultaneously fitted to a model assuming that ligands bound to two independent sites according to the law of mass action. Numbers are given as means  $\pm$  S.E.M. of 3–10 separate experiments each performed with duplicate determinations.

Fig. 2B shows the non-transformed saturation data shown in Fig. 2A. Fig. 2C shows the competition curves of BRL44408 using fixed concentrations of 0.93 or 4.1 nM of [ $^3$ H]RX821002. As may be seen from the figure the computer drawn lines from the simultaneous two-site fit of all data shown in Fig. 2 fit well the experimental data, indicating the validity of the model. (However, high concentrations of BRL44408 may displace some of the non-specific binding as there is some deviations from the fitted line above 10  $\mu$ M of BRL44408.)

### 3.3. Determination of drug $K_d$ values for $\alpha_{2A}$ - and $\alpha_{2C}$ -adrenoceptors in the pig cerebellum


### Competition studies using [3H]MK912 as ligand

In order to determine the  $K_d$  values of drugs for the  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors, competition studies were performed using [<sup>3</sup>H]MK912 in the pig cerebellum. The concentration of [<sup>3</sup>H]MK912 applied in these experiments was about 0.35 nM. At this concentration approximately 1/3 of the specific binding arises from the labelling of  $\alpha_{2C}$ -adrenoceptors and 2/3 from labelling of  $\alpha_{2A}$ -adrenoceptors. In each experiment three competition curves were obtained: one for the drug tested, one for the  $\alpha_{2A}$ -selective compound, BRL44408, and one for the drug tested in the presence of a fixed, predominantly  $\alpha_{2A}$  blocking, concentration of BRL 44408 (167 nM). The drugs selected for testing had been reported to be selective for  $\alpha_2$ -adrenoceptor subtypes in other species (Uhlén and Wikberg, 1991b; Uhlén et al., 1992, 1994, 1995). The results for the pig are shown in Fig. 3 and Table 2. As can be seen in Fig. 3 the competition curve for BRL44408 is clearly biphasic. The combined data from all tests gave  $K_d$  values of  $8.07 \pm 2.29$  nM and  $181 \pm 34$  nM (n = 8) for the  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptor, respectively. The reason for including BRL44408 in all tests was to accurately define the proportions of the  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors in each experiment, something which improves the accuracy of the determination of the  $K_d$  values for the drugs tested even when the drug shows low selectivity for the two  $\alpha_2$ -adrenoceptor subtypes. Moreover, the competition curve of the compound obtained in the

Table 3 Drug  $K_d$  ratios at porcine  $\alpha_{2A^-}$ ,  $\alpha_{2B^-}$  and  $\alpha_{2C}$ -adrenoceptors

Drug	$K_{ m d}$ ratio						
	$\alpha_{2B}$ kidney/ $\alpha_{2A}$ cerebellum	$\alpha_{2B}$ kidney/ $\alpha_{2A}$ kidney	$\alpha_{2C}$ cerebellum/ $\alpha_{2A}$ cerebellum	$\alpha_{2C}$ cerebellum/ $\alpha_{2A}$ kidney	$\alpha_{\rm 2B}$ kidney/ $\alpha_{\rm 2C}$ cerebellum		
RX821002	2.9	2.6	1.6	1.4	1.8		
MK912	0.95	1.1	0.12	0.14	7.8		
Rauwolscine	2.2	1.2	0.25	0.14	8.6		
WB4101	11	4.3	0.42	0.17	26		
BRL44408	60	65	22	24	2.7		
Oxymetazoline	160	81	<del>13</del>	6.4	12		
Spiroxatrine	0.075	0.037	0.045	0.022	1.7		
BRL41992	0.11	0.067	1.2	0.77	0.087		
ARC239	0.040	0.030	0.029	0.021	1.4		

Ratios are calculated from the  $K_d$  values shown in Table 2. The values representing the highest subtype selectivities are underlined.






Fig. 3. Competition curves of drugs at  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors obtained using [³H]MK912 and pig cerebellar membranes. In A and B are shown competition curves obtained by incubating the cerebellar membranes with  $\sim 0.35$  nM [³H]MK912 and various concentrations of BRL44408 ( $\blacksquare$ ), various concentrations of a test compound ( $\bullet$ ) or various concentrations of a test compound in the presence of a fixed concentration (167 nM) of BRL44408 ( $\blacktriangle$ ). The test compound was in A ARC239 and in B BRL41992. The curved lines represent the computer drawn fits obtained from the simultaneous fitting of all data in each experiment to a model that assumed that ligands bound to two independent sites according to the law of mass action.

presence of 167 nM of BRL44408 represents mainly competition at  $\alpha_{2C}$ -adrenoceptors, while the plain curve represents competition at both  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors. Thus the three competition curves in combination contain enough information to accurately determine the  $K_{\rm d}$  values of any drug tested for both the  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptor (see Uhlén and Wikberg, 1991b, for a full discussion on this topic).

The selectivities ( $K_{\rm d}$  ratios) of the drugs for the cerebellar  $\alpha_{\rm 2A}$ - and  $\alpha_{\rm 2C}$ -adrenoceptors are shown in Table 3. The most  $\alpha_{\rm 2A}$ -selective drug was BRL44408 (22-fold selective), whereas the most  $\alpha_{\rm 2C}$ -selective was ARC239 (34-fold selective). Fig. 3A shows the results


of a representative experiment using ARC239 as test compound. It may be noted that while the plain ARC239 competition curve is shallow the BRL44408-masked ARC239 competition curve aligns under the high-affinity portion of the plain curve. These data show that ARC239 has higher affinity for the  $\alpha_{2C}$ -adrenoceptor. Fig. 3B shows the results of a test using the  $\alpha_{2A}/\alpha_{2C}$ -adrenoceptor non-selective drug, BRL 41992. In these tests the BRL4408-blocked competition curve of BRL41992 (representing mainly the BRL41992 competing at  $\alpha_{2C}$ -adrenoceptors) is located under the middle/low-affinity portion of the plain BRL41992 competition curve. This indicates that BRL41992 is almost non-selective for the two  $\alpha_2$ -adrenoceptor subtypes in the pig cerebellum.

## 3.4. Determination of drug $K_d$ values for $\alpha_{2A}$ - and $\alpha_{2B}$ -adrenoceptors in the pig kidney cortex

### Competition studies using [3H]RX821002 as ligand

In order to determine the  $K_d$  values of drugs for the kidney cortex  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptors we used a fixed concentration of  $\approx 3$  nM of [<sup>3</sup>H]RX821002 and obtained competition curves using a design similar to that used for cerebellum. Thus, in each experiment one competition curve was obtained for the drug tested, one for the  $\alpha_{2A}$ -selective compound, BRL44408, and one for the drug tested in the presence of 316 nM BRL44408. As can be seen in Fig. 4 the competition curve for BRL44408 was slightly biphasic, reflecting its  $\alpha_{2A}$  versus  $\alpha_{2B}$  selectivity. The  $K_d$  values for BRL44408 were  $7.41 \pm 0.90$  nM and  $481 \pm 85$  nM (n = 10) for the  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptor subtypes, respectively. In the same way as described above for the cerebellum, the competition curve of BRL44408 helps to define the proportions of  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptors in the assay, while the competition curve of the test compound in the presence of 316 nM of BRL44408 represents competition (of the test compound) mainly at  $\alpha_{2B}$ adrenoceptors. The plain competition curve represents the competition of the test compound at both  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptors.

As can be seen from Table 3, the most  $\alpha_{2A}$ -selective drug was oxymetazoline (160-fold selective), whereas the most  $\alpha_{2B}$ -selective was ARC239 (33-fold selective). Fig. 4A shows the result of a test of ARC239. It may be noted that the BRL44408-blocked competition curve for ARC239 is located mainly under the high-affinity portion of the plain ARC239 competition curve, showing that ARC239 has higher affinity for the kidney cortex  $\alpha_2$ -adrenoceptors not blocked by BRL 44408. This indicates that ARC239 has the higher affinity for the  $\alpha_{2B}$ -adrenoceptor. Fig. 4B shows the result of a test of BRL41992. The BRL44408-blocked competition curve of BRL41992 is situated mainly under the high-affinity portion of the plain BRL41992 competition






Fig. 4. Competition curves of drugs at  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptors obtained using [ $^3$ H]RX821002 and pig kidney cortex membranes. In A and B are shown competition curves obtained by incubating kidney cortex membranes with  $\sim 3.4$  nM [ $^3$ H]RX821002 and various concentrations of BRL44408 ( $\blacksquare$ ), various concentrations of a test compound ( $\bullet$ ) or various concentrations of a test compound in the presence of a fixed concentration (316 nM) of BRL44408 ( $\blacktriangle$ ). The test compound was in A ARC239 and in B BRL41992. The solid lines represent the computer drawn fits obtained from the simultaneous fitting of all data in each experiment to a model that assumed that ligands bound to two independent sites according to the law of mass action.

curve. This indicates that BRL41992 also is  $\alpha_{2B}$ -selective in the pig kidney cortex.

### 4. Discussion

One of the aims of the present study was to develop assays to differentiate between porcine  $\alpha_2$ -adrenoceptor subtypes, and to identify subtype-selective drugs for these receptors. In the present study we have shown that [ $^3$ H]MK912 is useful to label the porcine cerebellar  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors while [ $^3$ H]RX821002 is

useful to label the porcine kidney  $\alpha_{2A}$  and  $\alpha_{2B}$ adrenoceptors. It can be noted that neither [3H]MK912 nor [3H]RX821002 have been reported to label any of the so called I receptors (imidazoline binding sites) (see Ernsberger, 1992; Miralles et al., 1993), so it is not likely that such sites have confounded the results of the present study. By including the  $\alpha_{2A}$ -selective drug, BRL44408, in the experimental design, each one of the porcine  $\alpha_{2A}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptor subtypes could be accurately characterized pharmacologically. Examples of our experimental design ('multicurve approach') are shown in Figs. 1, 2, 3, and 4. Also, we had previously shown our approach to be superior to the traditional one-curve methods for the delineation of receptor subtypes and the determination of drug affinities for closely related receptors (Uhlén and Wikberg, 1991a, b, 1992; Uhlén et al., 1992).

The numbers of  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors in the pig cerebellum (119 and 11 fmol/mg protein, established in the present study) were fairly equal to the numbers of the sites in the rat cerebellum (Uhlén and Wikberg, 1992). Also, the number of  $\alpha_{2A}$  sites in the pig kidney cortex (8.5 fmol/mg protein) was comparable to that in the rat (Uhlén and Wikberg, 1991b). However, the number of  $\alpha_{2B}$ -adrenoceptors in the pig kidney cortex was only about 9 fmol/mg protein, compared to 96 fmol/mg protein in the rat kidney (Uhlén and Wikberg, 1991b). The low number of  $\alpha_{2B}$ -adrenoceptors in the pig kidney was not due to a heterogenous distribution of  $\alpha_2$ -adrenoceptors within the kidney, since the identical number of sites was detected in the kidney medulla (data not shown). Instead, this large species difference is in line with the results of several recent studies reporting large species variations in the number and distribution of the  $\alpha_2$ -adrenoceptor subtypes (Blaxall et al., 1991; Trendelenburg et al., 1994; Berkowitz et al., 1994).

Table 3 gives the  $K_d$  ratios of 9 drugs tested for the porcine  $\alpha_{2A}$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$ -adrenoceptors. Several drugs were found to be subtype-selective for the pig  $\alpha_{2A}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptors. For example BRL44408 was found to be  $\alpha_{2A}$ -selective, BRL41992  $\alpha_{2B}$ -selective and MK912  $\alpha_{2C}$ -selective. In fact, our data suggest that a minimal set of these three drugs would suffice to differentiate between the three pig  $\alpha_2$ -adrenoceptor subtypes (cf. Table 2). Thus, a relatively high affinity, in accordance with that reported in Table 2, for one of the subtype-selective compounds would indicate the presence of the respective  $\alpha_2$ adrenoceptor subtype (see also Uhlén et al al. 1994 for a further discussion on this topic). In addition, WB4101 was found to have selectively low affinity for the  $\alpha_{2R}$ subtype, whereas ARC239 and spiroxatrine were found to have selectively low affinity for the  $\alpha_{2A}$  subtype.

The species homologues of the human  $\alpha_{2A}$ -adrenoceptor gene have been cloned from the pig, rat and

mouse. The deduced amino acid sequences of these receptors are 93, 89, and 92% identical with the human  $\alpha_{2A}$ -adrenoceptor sequence, respectively (see O'Rourke et al., 1994 and references therein). The rat/mouse/ bovine  $\alpha_{2A}$ -adrenoceptors have, from a pharmacological point of view, been denoted as ' $\alpha_{2D}$ '-adrenoceptors, due to differences in their pharmacology compared to the human and porcine  $\alpha_{2A}$ -adrenoceptors (see O'Rourke et al., 1994). Comparison of the  $K_{\rm d}$  values of drugs for  $\alpha_{2A}/(\alpha_{2D})^2$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$  adrenoceptors in different species shows that all three porcine  $\alpha_2$ -adrenoceptors are pharmacologically very close to the human  $\alpha_{2A}$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$ -adrenoceptors (cf. Table 2 of Uhlén et al., 1994; cf. also Devidjan et al., 1994). Comparison of the human/porcine  $\alpha_{2A}$ - and the rat ' $\alpha_{2D}$ '-adrenoceptor shows that WB4101 and rauwolscine, among other drugs, have higher affinity for the human/porcine  $\alpha_{2A}$ -adrenoceptors compared to the rat ' $\alpha_{2D}$ '-adrenoceptor (Uhlén et al., 1992), whereas BRL41992 shows higher affinity for the rat ' $\alpha_{2D}$ 'adrenoceptor than for either the human or pig  $\alpha_{2A}$ adrenoceptor. Thus, for the  $\alpha_{2A}$ -adrenoceptor of the human colonic HT29 cell line we found BRL41992 to have a  $K_d$  value of  $149 \pm 16$  nM (n = 3; Uhlén, personal communication), which is a value similar to the  $K_{\rm d}$  value of BRL41992 for the pig  $\alpha_{2A}$ -adrenoceptor (188–300 nM, see Table 2), but higher than the  $K_d$ value of BRL41992 for the ' $\alpha_{2D}$ '-adrenoceptor in the rat (28 nM, see Uhlén et al., 1992). BRL41992 is the first ' $\alpha_{2D}$ '- to  $\alpha_{2A}$ -selective drug that has been identified, something that had been wished for (O'Rourke et al., 1994). It can be noted that Devidjian et al. (1994) have reported lower  $K_d$  values of BRL41992 for the human  $\alpha_2$ -adrenoceptor subtypes compared to that we have found in the present study for the pig  $\alpha_2$ -adrenoceptor subtypes and for the human  $\alpha_{2A}$ -adrenoceptor. The reason for this discrepancy is not known at present. Altogether though, the data of the present study indicate that the pig  $\alpha_2$ -adrenoceptor subtypes are pharmacologically more related to the human  $\alpha_2$ adrenoceptor subtypes than to the  $\alpha_2$ -adrenoceptors of other well characterized mammalian species.

In summary, we have now shown that [ ${}^{3}H$ ]MK912 is useful to label  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors in the pig cerebellum, and that [ ${}^{3}H$ ]RX821002 is useful to label  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenoceptors in the pig kidney cortex. Including the  $\alpha_{2A}$ -selective drug, BRL44408, in the experimental designs allows estimates of drug affinities for all the three pig  $\alpha_{2}$ -adrenoceptor subtypes to be obtained. The evaluated tissues may be viewed as sources of prototypic  $\alpha_{2A}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptors in the pig. Finally BRL44408, BRL41992 and MK912 along with ARC239, WB4101 and spiroxatrine were identified as subtype-selective compounds useful for differentiating between the pig  $\alpha_{2A}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptor subtypes.

### Acknowledgements

Supported by the Swedish MRC 04X-05957, the Magnus Bergwalls Foundation, the Groschinsky Foundation, the Åke Wiberg Foundation and the Crown Princess Margareta Foundation.

#### References

- Berkowitz, D.E., D.T. Price, E.A. Bello, S.O. Page and D.A. Schwinn, 1994, Localization of messenger RNA for three distinct α<sub>2</sub>adrenergic receptor subtypes in human tissues, Anesthesiology 81 (5), 1235.
- Blaxall, H.S., T.J. Murphy, J.C. Baker, C. Ray and D.B. Bylund, 1991, Characterization of the alpha-2C adrenergic receptor subtype in the opossum kidney and in the OK cell line, J. Pharmacol. Exp. Ther. 259(1), 323.
- Blaxall, H.S., D.R. Cerutis, N.A. Hass, L.J. Iversen and D.B. Bylund, 1994, Cloning and expression of the alpha-2C-adrenergic receptor from the OK cell line, Mol. Pharmacol. 45, 176.
- Bylund, D.B., D.C. Eikenberg, J.P. Hieble, S.Z. Langer, R.J. Lefkowitz, K.P. Minneman, P.B. Molinoff, R.R. Ruffolo Jr. and U. Trendelenburg, 1994, IV. International Union of Pharmacology Nomenclature of Adrenoceptors, Pharmacol. Rev. 46, 121.
- Devedjian, J.-C., F. Esclapez, C. Denis-Pouxviel and H. Paris, 1994, Further characterization of human alpha-2 adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs, Eur. J. Pharmacol. 252, 43.
- Ernsberger, P., 1992, Heterogeneity of imidazoline binding sites: proposed I<sub>1</sub> and I<sub>2</sub> subtypes, Fundam. Clin. Pharmacol. 6 (Suppl. 1), 55s.
- Guyer, C.A., D.A. Horstman, A.L. Wilson, J.D. Clark, E.J. Cragoe Jr. and L.E. Limbird, 1990, Cloning, sequencing, and expression of the gene encoding the porcine alpha 2-adrenergic receptor. Allosteric modulation by Na<sup>+</sup>, H<sup>+</sup>, and amiloride analogs, J. Biol. Chem. 265, 17307.
- Harrison, J.K., D.D. D'Angelo, D. Zeng and K.R. Lynch, 1991b, Pharmacological characterization of rat  $\alpha_2$ -adrenergic receptors, Mol. Pharmacol. 40, 407.
- Langin, D., M. Lafontan, M.R. Stillings and H. Paris, 1989, [ $^3$ H]RX821002: a new tool for the identification of  $\alpha_{2\Lambda}$ -adrenoceptors, Eur. J. Pharmacol. 167, 95.
- Lowry, O.H., N.J. Rosebrough, A.L. Farr and R.J. Randall, 1951, Protein measurement with the Folin phenol reagent, J. Biol. Chem. 193, 265.
- Miralles, A., G. Olmos, M. Sastre, F. Barturen, I. Martin and J.A. Garcia-Sevilla, 1993, Discrimination and pharmacological characterization of  $1_2$ -imidazoline sites with [ $^3$ H]idazoxan and  $\alpha_2$ -adrenoceptors with [ $^3$ H]RX821002 (2-methoxy-idazoxan) in the human and rat brains, J. Pharmacol. Exp. Ther. 264, 1187.
- O'Rourke. M.F., L.J. Iversen, J.W. Lomasney and D.B. Bylund, 1994, Species orthologs of the alpha-2A adrenergic receptor: the pharmacological properties of the bovine and rat receptors differ from the human and porcine receptors, J. Pharmacol. Exp. Ther. 271, 735.
- Trendelenburg, A.-U., N. Limberger and L.C. Rump, 1994,  $\alpha_2$ -Adrenergic receptors of the  $\alpha_{2C}$  subtype mediate inhibition of norepinephrine release in human kidney cortex, Mol. Pharmacol. 45, 1168.
- Uhlén, S. and J.E.S. Wikberg, 1991a, Rat spinal cord  $\alpha_2$ -adrenoceptors are of the  $\alpha_{2A}$ -subtype: comparison with  $\alpha_{2A}$  and  $\alpha_{2B}$ -adrenoceptors in rat spleen, cerebral cortex and kidney using  ${}^3\text{HRX821002}$  ligand binding, Pharmacol. Toxicol. 69, 341.
- Uhlén, S. and J.E.S. Wikberg, 1991b, Delineation of rat kidney  $\alpha_{2A}$  and  $\alpha_{2B}$  adrenoceptors with <sup>3</sup>HRX821002 radioligand binding:

- computer modelling reveals that guanfacine is an  $\alpha_{2A}$ -selective compound, Eur. J. Pharmacol. 202, 235.
- Uhlén, S. and J.E.S. Wikberg, 1992, [ $^3$ H]MK912: a novel  $\alpha_{2C}$ -adrenoceptor selective ligand detects both  $\alpha_{2A}$  and  $\alpha_{2C}$ -adrenoceptors in the cerebellum, DuPont/BiotechUpdate 7, 16.
- Uhlén, S., Y. Xia, V. Chhajlani, C.C. Felder and J.E.S. Wikberg, 1992, [ $^3$ H]MK912 binding delineates two  $\alpha_2$ -adrenoceptor subtypes in rat CNS one of which is identical with the cloned pA2d  $\alpha_2$ -adrenoceptor, Br. J. Pharmacol. 106, 986.
- Uhlén, S., Y. Xia, V. Chhajlani, E.J. Lien and J.E.S. Wikberg, 1993, Evidence for the existence of two forms of  $\alpha_{2A}$ -adrenoceptors in the rat. Naunyn-Schmied. Arch. Pharmacol. 347, 280.
- Uhlén, S., A.S. Porter and R.R. Neubig, 1994, The novel  $\alpha_2$ -adrenergic antagonist radioligand [ $^3$ H]MK912 is  $\alpha_{2C}$ -selective among human  $\alpha_{2A}$ -,  $\alpha_{2B}$ -, and  $\alpha_{2C}$ -adrenoceptors, J. Pharmacol. Exp. Ther. 271, 1558.
- Uhlén, S., R. Muceniece, N. Rangel, G. Tiger and J.E.S. Wikberg, 1995, Comparison of the binding activities of some drugs on  $\alpha_{2A}$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$ -adrenoceptors and non-adrenergic imidazoline sites in the guinea pig, Pharmacol. Toxicol. 76, 353.
- Xia, Y., S. Uhlén, V. Chhajlani, E.J. Lien and J.E.S. Wikberg, 1993, Further evidence for the existence of two forms of  $\alpha_{2B}$ -adrenoceptors in the rat. Pharmacol. Toxicol. 72, 40.